---
title: Small Vessel Vasculitis ANCA-Associated Vasculitides (AAV)
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[Huppert's Notes]]

# Small Vessel Vasculitis ANCA-Associated Vasculitides (AAV) #ðŸš§ æ–½å·¥ä¸­

### Small Vessel Vasculitis: ANCA-Associated Vasculitides (AAV)

Granulomatosis with polyangiitis (GPA, formerly Wegenerâ€™s granulomatosis)

â€¢Â Â Â Epidemiology: Incidence of 7â€“12/million individuals annually. Typical age of onset 45â€“60 yr.

â€¢Â Â Â Diagnosis:

-Â Â Â Most patients with systemic disease are c-ANCA and anti-PR3 positive

-Â Â Â Tissue biopsy showing pauci-immune necrotizing granulomatous vasculitis is gold standard

â€¢Â Â Â Clinical features:

-Â Â Â **ENT** (70â€“100%): Sinusitis, rhinorrhea, otitis media, chondritis of the ears and nose with saddle nose deformity, nasal septal perforation

-Â Â Â **Pulm** (50â€“90%): Cavitary nodules, diffuse alveolar hemorrhage, tracheal subglottic stenosis

-Â Â Â **Renal** (40â€“100%): Pauci-immune necrotizing glomerulonephritis

-Â Â Â **Derm** (10â€“50%): Palpable purpura, nodules, pyoderma gangrenosum

-Â Â Â **Neuro** (30%): Mononeuritis multiplex, distal symmetric polyneuropathy, pachymeningitis

-Â Â Â **Ocular** (15â€“60%): Posterior uveitis, scleritis, episcleritis, retro-orbital pseudotumor, dacryoadenitis (lacrimal gland inflammation)

-Â Â Â **Cardiac** (<10%): Pericarditis, myocarditis, conduction disorder

-Â Â Â **GI** (5â€“10%): Ulceration

â€¢Â Â Â Treatment:

-Â Â Â Systemic organ-threatening disease:

**â€¢**Â Â Â Induction therapy: Pulse dose glucocorticoids (1 g per day Ã— 3â€“5 days) followed by 1 mg/kg, then add rituximab or cyclophosphamide. Rituximab is non-inferior to cyclophosphamide for induction therapy in ANCA\+ GPA and MPA (**RAVE *New Engl J Med* 2010**) and is associated with less infertility and alopecia.

**â€¢**Â Â Â Maintenance therapy: Rituximab for 12â€“24 months after remission, azathioprine, or methotrexate

-Â Â Â Limited upper airway disease: Glucocorticoids plus methotrexate or rituximab

##### Microscopic polyangiitis (MPA)

â€¢Â Â Â Epidemiology: Incidence of 2.7â€“94/million individuals annually. Average age of onset is 50â€“60 yr

â€¢Â Â Â Diagnosis:

-Â Â Â Small vessel vasculitis of the lungs (diffuse alveolar hemorrhage) and kidneys (crescentic RPGN)

-Â Â Â 50â€“75% ANCA\+ and generally p-ANCA and anti-MPO positive

-Â Â Â Tissue biopsy is the gold standard and shows non-granulomatous necrotizing pauci-immune vasculitis (as opposed to granulomatous in GPA)

â€¢Â Â Â Clinical features:

-Â Â Â **Renal** (80â€“100%): Necrotizing glomerulonephritis

-Â Â Â **Derm** (30â€“60%): Palpable purpura with histology showing leukocytoclastic vasculitis; livedo reticularis; nodules; necrotic skin ulcers

-Â Â Â **Neuro** (30â€“70%): Mononeuritis multiplex; distal symmetric polyneuropathy; pachymeningitis

-Â Â Â **Pulm** (25â€“55%): Diffuse alveolar hemorrhage, organizing pneumonia, ILD with radiographic phenotype of usual interstitial pneumonia (UIP)

-Â Â Â **ENT** (10â€“30%): Sinusitis; sensorineural hearing loss

â€¢Â Â Â Treatment: Similar to treatment of GPA

##### Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome)

â€¢Â Â Â Epidemiology: Rarest ANCA-associated vasculitis; 0.1â€“2.66/million individuals annually

â€¢Â Â Â Diagnosis:

-Â Â Â Small vessel vasculitis that typically occurs in patients with preceeding adult-onset asthma and nasal polyps

-Â Â Â 50% ANCA\+ and usually p-ANCA and anti-MPO positive

-Â Â Â Eosinophilia >1500 cells/Î¼LÂ often present

-Â Â Â Diagnostic gold standard is biopsy of involved tissue (e.g., nerve) showing pauci-immune necrotizing granulomatous vasculitis with eosinophilic infiltration of vessel walls and tissues (eosinophilic infiltration distinguishes EGPA from MPA and GPA)

â€¢Â Â Â Clinical features:

-Â Â Â **Neuro** (70%): Mononeuritis multiplex or distal sensory polyneuropathy

-Â Â Â **Pulm:** Most patients (95â€“100%) have preceding asthma that often improves during the vasculitic phase. Patients also may have migratory pulmonary consolidations similar to those seen with eosinophilic pneumonia during the vasculitis phase

-Â Â Â **Cardiac** (20â€“40%): Pericarditis, endomyocarditis, conduction system disease, CHF

-Â Â Â **Renal** (25%): Pauci-immune glomerulonephritis

â€¢Â Â Â Treatment:

-Â Â Â Glucocorticoids alone may be sufficient unless there is major organ involvement, in which case cyclophosphamide is indicated

-Â Â Â Lowest mortality among all the ANCA-associated vasculitidies (5 yr survival 97%)

